|
Gene: ERBB3 |
Gene summary for ERBB3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ERBB3 | Gene ID | 2065 |
Gene name | erb-b2 receptor tyrosine kinase 3 | |
Gene Alias | ErbB-3 | |
Cytomap | 12q13.2 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | P21860 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2065 | ERBB3 | GSM4909285 | Human | Breast | IDC | 6.98e-03 | 2.54e-01 | 0.21 |
2065 | ERBB3 | GSM4909293 | Human | Breast | IDC | 2.67e-14 | 3.89e-01 | 0.1581 |
2065 | ERBB3 | GSM4909296 | Human | Breast | IDC | 7.91e-05 | -7.77e-02 | 0.1524 |
2065 | ERBB3 | GSM4909297 | Human | Breast | IDC | 1.09e-02 | -1.83e-02 | 0.1517 |
2065 | ERBB3 | GSM4909298 | Human | Breast | IDC | 2.36e-21 | 5.99e-01 | 0.1551 |
2065 | ERBB3 | GSM4909301 | Human | Breast | IDC | 7.73e-11 | 5.31e-01 | 0.1577 |
2065 | ERBB3 | GSM4909302 | Human | Breast | IDC | 4.33e-04 | 3.39e-01 | 0.1545 |
2065 | ERBB3 | GSM4909306 | Human | Breast | IDC | 3.85e-07 | 3.75e-01 | 0.1564 |
2065 | ERBB3 | GSM4909307 | Human | Breast | IDC | 1.13e-04 | 3.13e-01 | 0.1569 |
2065 | ERBB3 | GSM4909311 | Human | Breast | IDC | 6.99e-21 | -3.27e-02 | 0.1534 |
2065 | ERBB3 | GSM4909312 | Human | Breast | IDC | 7.40e-11 | 2.00e-01 | 0.1552 |
2065 | ERBB3 | GSM4909319 | Human | Breast | IDC | 9.66e-22 | -2.08e-01 | 0.1563 |
2065 | ERBB3 | GSM4909320 | Human | Breast | IDC | 1.13e-03 | 7.80e-02 | 0.1575 |
2065 | ERBB3 | GSM4909321 | Human | Breast | IDC | 7.10e-11 | 9.48e-02 | 0.1559 |
2065 | ERBB3 | M1 | Human | Breast | IDC | 6.46e-10 | 5.43e-01 | 0.1577 |
2065 | ERBB3 | NCCBC14 | Human | Breast | DCIS | 4.66e-05 | -1.89e-01 | 0.2021 |
2065 | ERBB3 | NCCBC2 | Human | Breast | DCIS | 2.05e-03 | 3.00e-01 | 0.1554 |
2065 | ERBB3 | NCCBC5 | Human | Breast | DCIS | 5.81e-06 | -2.35e-01 | 0.2046 |
2065 | ERBB3 | P1 | Human | Breast | IDC | 5.34e-09 | 3.21e-02 | 0.1527 |
2065 | ERBB3 | DCIS2 | Human | Breast | DCIS | 4.90e-51 | 1.24e-01 | 0.0085 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719114 | Breast | IDC | extrinsic apoptotic signaling pathway | 42/1434 | 219/18723 | 2.56e-08 | 1.73e-06 | 42 |
GO:007099714 | Breast | IDC | neuron death | 57/1434 | 361/18723 | 1.31e-07 | 7.38e-06 | 57 |
GO:005140213 | Breast | IDC | neuron apoptotic process | 42/1434 | 246/18723 | 7.21e-07 | 3.35e-05 | 42 |
GO:190121414 | Breast | IDC | regulation of neuron death | 48/1434 | 319/18723 | 5.01e-06 | 1.69e-04 | 48 |
GO:004352313 | Breast | IDC | regulation of neuron apoptotic process | 35/1434 | 212/18723 | 1.26e-05 | 3.29e-04 | 35 |
GO:004206014 | Breast | IDC | wound healing | 55/1434 | 422/18723 | 7.27e-05 | 1.45e-03 | 55 |
GO:004352411 | Breast | IDC | negative regulation of neuron apoptotic process | 23/1434 | 145/18723 | 6.58e-04 | 8.11e-03 | 23 |
GO:004206311 | Breast | IDC | gliogenesis | 39/1434 | 301/18723 | 8.63e-04 | 1.00e-02 | 39 |
GO:00100011 | Breast | IDC | glial cell differentiation | 31/1434 | 225/18723 | 1.04e-03 | 1.15e-02 | 31 |
GO:190121513 | Breast | IDC | negative regulation of neuron death | 29/1434 | 208/18723 | 1.23e-03 | 1.32e-02 | 29 |
GO:00071625 | Breast | IDC | negative regulation of cell adhesion | 37/1434 | 303/18723 | 3.27e-03 | 2.75e-02 | 37 |
GO:007099724 | Breast | DCIS | neuron death | 57/1390 | 361/18723 | 4.56e-08 | 2.84e-06 | 57 |
GO:009719123 | Breast | DCIS | extrinsic apoptotic signaling pathway | 40/1390 | 219/18723 | 9.43e-08 | 5.28e-06 | 40 |
GO:005140222 | Breast | DCIS | neuron apoptotic process | 43/1390 | 246/18723 | 1.16e-07 | 6.13e-06 | 43 |
GO:190121421 | Breast | DCIS | regulation of neuron death | 48/1390 | 319/18723 | 2.13e-06 | 7.79e-05 | 48 |
GO:004352321 | Breast | DCIS | regulation of neuron apoptotic process | 36/1390 | 212/18723 | 2.45e-06 | 8.68e-05 | 36 |
GO:004206024 | Breast | DCIS | wound healing | 54/1390 | 422/18723 | 6.09e-05 | 1.22e-03 | 54 |
GO:004352421 | Breast | DCIS | negative regulation of neuron apoptotic process | 23/1390 | 145/18723 | 4.27e-04 | 5.72e-03 | 23 |
GO:00420632 | Breast | DCIS | gliogenesis | 39/1390 | 301/18723 | 4.76e-04 | 6.25e-03 | 39 |
GO:00100012 | Breast | DCIS | glial cell differentiation | 31/1390 | 225/18723 | 6.24e-04 | 7.87e-03 | 31 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0520542 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa0520552 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa04012 | Colorectum | AD | ErbB signaling pathway | 31/2092 | 85/8465 | 1.02e-02 | 3.91e-02 | 2.50e-02 | 31 |
hsa01521 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa040121 | Colorectum | AD | ErbB signaling pathway | 31/2092 | 85/8465 | 1.02e-02 | 3.91e-02 | 2.50e-02 | 31 |
hsa015211 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa040122 | Colorectum | MSS | ErbB signaling pathway | 30/1875 | 85/8465 | 3.73e-03 | 1.67e-02 | 1.02e-02 | 30 |
hsa052055 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa040123 | Colorectum | MSS | ErbB signaling pathway | 30/1875 | 85/8465 | 3.73e-03 | 1.67e-02 | 1.02e-02 | 30 |
hsa052056 | Colorectum | FAP | Proteoglycans in cancer | 57/1404 | 205/8465 | 3.05e-05 | 3.29e-04 | 2.00e-04 | 57 |
hsa015212 | Colorectum | FAP | EGFR tyrosine kinase inhibitor resistance | 26/1404 | 79/8465 | 2.69e-04 | 2.19e-03 | 1.33e-03 | 26 |
hsa040124 | Colorectum | FAP | ErbB signaling pathway | 26/1404 | 85/8465 | 9.52e-04 | 5.22e-03 | 3.17e-03 | 26 |
hsa04010 | Colorectum | FAP | MAPK signaling pathway | 68/1404 | 302/8465 | 4.00e-03 | 1.67e-02 | 1.02e-02 | 68 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | Breast | DCIS |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | Breast | DCIS |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | Cervix | CC |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | Cervix | Precancer |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | Cervix | Precancer |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | CRC | AD |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | CRC | AD |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | CRC | ADJ |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | CRC | ADJ |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | CRC | FAP |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | CRC | FAP |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | CRC | MSS |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | CRC | MSS |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | Esophagus | ESCC |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | Esophagus | ESCC |
NRG2 | ERBB3 | NRG2_ERBB3 | NRG | Esophagus | ESCC |
NRG2 | ERBB2_ERBB3 | NRG2_ERBB2_ERBB3 | NRG | Esophagus | ESCC |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | GC | ADJ |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | GC | GC |
NRG1 | ERBB3 | NRG1_ERBB3 | NRG | HNSCC | OSCC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERBB3 | SNV | Missense_Mutation | c.1292N>C | p.Leu431Ser | p.L431S | P21860 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ERBB3 | SNV | Missense_Mutation | c.310N>A | p.Val104Met | p.V104M | P21860 | protein_coding | deleterious(0.05) | possibly_damaging(0.64) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ERBB3 | SNV | Missense_Mutation | c.917N>A | p.Pro306His | p.P306H | P21860 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ERBB3 | SNV | Missense_Mutation | c.383N>A | p.Ser128Asn | p.S128N | P21860 | protein_coding | tolerated(0.62) | benign(0.052) | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ERBB3 | SNV | Missense_Mutation | rs759113437 | c.355N>A | p.Val119Ile | p.V119I | P21860 | protein_coding | tolerated(0.52) | benign(0.121) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | c.1999C>A | p.Arg667Ser | p.R667S | P21860 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BR-6454-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ERBB3 | SNV | Missense_Mutation | c.2012T>A | p.Ile671Asn | p.I671N | P21860 | protein_coding | deleterious(0) | possibly_damaging(0.89) | TCGA-BR-6563-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | doxorubicin | CR | |
ERBB3 | SNV | Missense_Mutation | c.310N>T | p.Val104Leu | p.V104L | P21860 | protein_coding | deleterious(0.03) | benign(0.119) | TCGA-BR-6706-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
ERBB3 | SNV | Missense_Mutation | c.3710G>A | p.Ser1237Asn | p.S1237N | P21860 | protein_coding | tolerated(0.16) | possibly_damaging(0.614) | TCGA-BR-8059-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
ERBB3 | SNV | Missense_Mutation | c.310G>A | p.Val104Met | p.V104M | P21860 | protein_coding | deleterious(0.05) | possibly_damaging(0.64) | TCGA-BR-8078-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | antibody | 252827373 | ELGEMTUMAB | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | TRASTUZUMAB | TRASTUZUMAB | 23680147 | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | 178101724 | |||
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | lapatinib | LAPATINIB | ||
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | CHEMBL2109406 | PATRITUMAB | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | DACOMITINIB | DACOMITINIB | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | CDX-3379 | |||
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 315661317 | ||
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | LAPATINIB | LAPATINIB | 25953157,25398453 | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | PERTUZUMAB | PERTUZUMAB | 23680147 |
Page: 1 2 3 4 5 6 7 8 |